Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ho PM, et al. JAMA 2009;301:937-44. Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:937-44.

Published byLorraine Green Modified over 9 years ago

Similar presentations

Presentation on theme: "Ho PM, et al. JAMA 2009;301:937-44. Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:937-44."— Presentation transcript:

1 Ho PM, et al. JAMA 2009;301:937-44

2 Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:937-44

3 Adverse Outcomes Following Hospital Discharge for Acute Coronary Syndrome (ACS) Ho PM, et al. JAMA 2009;301:937-44

4 Cumulative Risk of All-Cause Mortality and Recurrent Acute Coronary Syndrome (ACS) Among Patients Taking Clopidogrel After Hospital Discharge for ACS and Prescribed a Proton Pump Inhibitor (PPI) at Hospital Discharge or During Follow-up (n=5244) Ho PM, et al. JAMA 2009;301:937-44

5 Risk of Death or Rehospitalization While Taking Clopidogrel and a Proton Pump Inhibitor (PPI) Following Hospital Discharge for Acute Coronary Syndrome Ho PM, et al. JAMA 2009;301:937-44

Download ppt "Ho PM, et al. JAMA 2009;301:937-44. Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:937-44."

Similar presentations

David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]

David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.

PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.

ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation 20002005 and beyond Surrogate outcomes studies Large.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.

Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results www.shift-study.com Swedberg K, et al. Lancet. 2010;376(9744):875-885.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
MERLIN TIMI 36 M ETABOLIC E FFICIENCY WITH R ANOLAZINE FOR L ESS I SCHEMIA IN N STE ACS.

MERLIN TIMI 36 M ETABOLIC E FFICIENCY WITH R ANOLAZINE FOR L ESS I SCHEMIA IN N STE ACS.
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013.

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
INTRODUCTION Dual antiplatelet therapy is a cornerstone of medical therapy for patients undergoing percutaneous coronary intervention (PCI) for coronary.

INTRODUCTION Dual antiplatelet therapy is a cornerstone of medical therapy for patients undergoing percutaneous coronary intervention (PCI) for coronary.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Similar presentations

Ads by Google